The use of 4F-PCC to correct direct oral anticoagulant-induced coagulopathy: An observational analysis.

Our data showed that 4F-PCC was relatively efficient in correcting DOAC-induced coagulopathy. We did notice that 16.7% of patients experienced some form of thromboembolic events in the days-to-weeks after 4F-PCC administration, although the imputability of 4F-PCC in these processes (vs their underlying disease) is difficult to determine. Additional prospective studies would be warranted to further evaluate the safety of 4F-PCC for this off-label indication.